Exodus Point Capital Management, LP Ascendis Pharma A/S Transaction History

Exodus Point Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$86.5 - $103.97 $1.19 Million - $1.43 Million	13,743 New	13,743 $1.29 Million
Q3 2021 Nov 15, 2021	SELL	$112.67 - $176.92 $218,129 - $342,517	-1,936 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$121.62 - $145.29 $126,484 - $151,101	-1,040 Reduced 34.95%	1,936 $255,000
Q1 2021 May 17, 2021	BUY	$124.92 - $173.33 $206,992 - $287,207	1,657 Added 125.63%	2,976 $384,000
Q4 2020 Feb 16, 2021	BUY	$151.2 - $182.76 $199,432 - $241,060	1,319 New	1,319 $220,000
Q4 2019 Feb 14, 2020	SELL	$91.45 - $139.12 $1.23 Million - $1.88 Million	-13,482 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$95.8 - $118.9 $1.53 Million - $1.9 Million	-16,009 Reduced 54.28%	13,482 $1.3 Million
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $1.44 Million - $1.78 Million	-13,463 Reduced 31.34%	29,491 $3.4 Million
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $2.67 Million - $5.58 Million	42,954 New	42,954 $5.06 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.